Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 9/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 7/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500610 | 0.85 | KCNH2 (0.38) | KCNH2SCN3AMAOB | |
| SCHEMBL2585801 | 0.83 | SLC6A3 (0.41) | KCNH2SCN3AGRIA4TAS1R3TAS1R1 | |
| SCHEMBL4089338 | 0.83 | KCNH2 (0.52) | KCNH2SCN3A | |
| SCHEMBL8442870 | 0.80 | KCNH2 (0.41) | KCNH2SCN3AGRIA4 | |
| SCHEMBL4333611 | 0.80 | KCNH2 (0.40) | KCNH2SCN3A | |
| SCHEMBL20835562 | 0.78 | KCNH2 (0.42) | KCNH2SCN3AMAOBTAS1R3TAS1R1 | |
| SCHEMBL31289648 | 0.78 | DPP4 (0.47) | KCNH2SCN3A | |
| SCHEMBL8870852 | 0.78 | DPP4 (0.47) | KCNH2SCN3A | |
| SCHEMBL31289649 | 0.78 | DPP4 (0.47) | KCNH2SCN3A | |
| Hydrochloric Acid SCHEMBL31289646 | 0.76 | DPP4 (0.46) | KCNH2SCN3AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1953158-B1 | BICYCLIC CINNAMIDE COMPOUND | EISAI R&D MAN CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | KIMURA TEIJI | 2009-07-16 | — | — | US | disclosed |
| EP-1953154-A1 | MORPHOLINE TYPE CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1953158-A1 | BICYCLIC CINNAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2008-08-06 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181945-A1 | TWO CYCLIC CINNAMIDE COMPOUND | APP, BACE1, PSEN1 | KCNH2 2785/4885SCN3A 1511/4885GRIA4 2251/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | KCNH2 2785/4885SCN3A 1511/4885GRIA4 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.